Table 1.
Baseline patient characteristics
| IMEP+L (n=22) | IMEP+P (n=19) | p-value | |
|---|---|---|---|
| Age (yr) | |||
| < 60 | 12 (54.5) | 13 (68.4) | 0.364 |
| ≥ 60 | 10 (45.5) | 6 (31.6) | |
| Median (75% CI) | 58.8 (44.4-68.8) | 55.9 (49.8-63.6) | 0.896 |
| Sex | |||
| Male | 12 (54.5) | 8 (42.1) | 0.427 |
| Female | 10 (45.5) | 11 (57.9) | |
| Presentation | |||
| UAT | 19 (86.4) | 14 (73.7) | 0.436 |
| Not UAT | 3 (13.6) | 5 (26.3) | |
| B symptoms | |||
| No | 15 (68.2) | 17 (89.5) | 0.140 |
| Yes | 7 (31.8) | 2 (10.5) | |
| Ann Arbor stage | |||
| I-II | 11 (50.0) | 10 (52.6) | 0.867 |
| III-IV | 11 (50.0) | 9 (47.4) | |
| LDH level | |||
| Normal | 11 (50.0) | 13 (68.4) | 0.233 |
| Elevated | 11 (50.0) | 6 (31.6) | |
| No. of extranodal sites | |||
| 0-1 | 17 (77.3) | 16 (84.2) | 0.703 |
| ≥ 2 | 5 (22.7) | 3 (15.8) | |
| ECOG PS | |||
| 0-1 | 20 (90.9) | 16 (84.2) | 0.649 |
| ≥ 2 | 2 (9.1) | 3 (15.8) | |
| IPI score | |||
| 0-1 | 11 (50.0) | 10 (52.6) | 0.300 |
| 2 | 4 (18.2) | 7 (36.8) | |
| 3 | 5 (22.7) | 1 (5.3) | |
| 4-5 | 2 (9.1) | 1 (5.3) | |
| KPI score | |||
| 1 | 4 | 2 | 0.006 |
| 2 | 7 | 6 | |
| 3 | 1 | 9 | |
| 4 | 10 | 2 | |
| PINK | |||
| Low | 4 | 4 | 0.917 |
| Intermediate | 13 | 10 | |
| High | 5 | 5 | |
| PINK/E | |||
| Low | 5 | 4 | 0.977 |
| Intermediate | 12 | 11 | |
| High | 5 | 4 | |
| Previous chemotherapy | |||
| 0 | 15 (68.2) | 14 (73.7) | 0.634 |
| 1-2 | 6 (27.3) | 5 (26.3) | |
| 3 | 1 (4.5) | 0 | |
| AST, median (75% CI) | 33.50 (21.75-110.25) | 22.0 (17.0-49.0) | 0.169 |
| ALT, median (75% CI) | 41.50 (19.50-62.75) | 20.0 (13.0-47.0) | 0.089 |
| ALP, median (75% CI) | 62.50 (52.25-132.25) | 94.0 (79.0-133.0) | 0.075 |
| t-bil, median (75% CI) | 0.65 (0.40-1.00) | 0.5 (0.4-0.7) | 0.323 |
| Albumin, median (75% CI) | 3.65 (3.175-4.15) | 3.8 (3.1-4.2) | 0.733 |
| Fibrinogen, median (75% CI)a) | 295.0 (214.5-392) | 321.0 (169.0-397.0) | 0.959 |
IMEP+L/P, ifosfamide, mesna, etoposide, prednisolone+L-asparaginase/peg-asparaginase; CI, confidence interval; UAT, upper aerodigestive tract; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; KPI, Korean Prognostic Index; PINK, Prognostic Index of Natural Killer Lymphoma; PINK/E, PINK-Epstein-Barr virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; t-bil, total bilirubin.
a)
Evaluated in 27 patients.